Q-omics provides the consensus-scored TAF4B profile across patient tissues and cancer cell-line models. TAF4B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TAF4B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TAF4B RNA expression shows 20,756 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where TAF4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF4B survival associations across molecular data types. TAF4B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF4B RNA expression–survival associations across cancer types. High TAF4B expression shows unfavorable associations in KIRP, BLCA, UCEC, ACC and UVM, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TAF4B RNA expression.
This table summarizes TAF4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TAF4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF4B shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, COAD, KIRC and LUSC. The HNSC box plot shows higher TAF4B RNA expression in tumor versus normal tissue (log2 FC = +0.918, t-test p < 0.001).
This table shows molecular features associated with TAF4B in patient tissues and cancer cell lines. In patient samples, TAF4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
